This author has yet to write their bio.Meanwhile lets just say that we are proud BioSpace contributed a whooping 4538 entries.
Just as Emergent BioSolutions looked to be making some headway in course corrections following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine, new information indicates the Maryland-based company sought to hide the deficiencies from federal regulators, all while touting its manufacturing capabilities, according to a BioSpace article.
In the company’s financial results for 2021 released on May 11, Takeda announced the decision to discontinue the development of TAK-609, a therapeutic for Hunter Syndrome. Additionally, Takeda is collaborating with JCR Pharmaceuticals in another therapeutic attempt for the condition.
The U.S. Food and Drug Administration granted approval for the commercialization of Eli Lilly and Company and Incyte Corporation’s Olumiant (baricitinib), setting a precedent for COVID-19 treatments.
Current COVID-19 booster shots have a problem: they last only about four months and appear to have limited efficacy in a vaccinated population. Clearly, a more durable, more efficacious vaccine is needed, but what should it be? The scientific community has not reached a consensus, according to BioSpace.
The Institute for Clinical and Economic Review recommended two out of three outpatient treatments for COVID-19 in the market, singling out molnupiravir as having inadequate evidence to support claims that it is better than symptomatic care.
AstraZeneca and Sanofi’s Phase III and Phase IIb clinical trials investigating the efficacy of nirsevimab, measured through the development of secondary infections, are impressing the pharma community with positive prespecified pooled analysis results. The data shows 79.5 percent efficacy in the prevention of lower respiratory tract infections, caused by infection of the respiratory syncytial virus (RSV).
A study published in Nature Communications describes how researchers at the United Kingdom Research Institute at the University of Cambridge stumbled upon a potential target of dementia research.
Cortexyme, a company focusing on treatments for degenerative diseases, entered into a deal to acquire Novosteo, which plays in the rare disease space. Once the deal is finalized, the merged companies will operate under the name Quince Therapeutics and trade under the ticker symbol QNCX.
Twist Bioscience and Astellas have entered into a research collaboration and exclusive option license agreement to identify potential therapeutic antibodies which would help to reduce tumor microenvironment-mediated immunosuppression.
Eisai and Biogen completed the rolling submission of a Biologics License Application for their proposed Alzheimer’s disease drug to the U.S. Food and Drug Administration.